To detect cystic fibrosis (CF) gene mutations; to screen for or help diagnose CF; to determine whether you are a carrier of a CF genetic mutation and to evaluate the risk of having a baby with CF

When To Get Tested?

When screening newborns for CF (all U.S. states screen for CF and some states use this test for screening); when an older child or adult has signs and symptoms of CF or a positive CF screening test; when someone wants to know their carrier status, such as a woman who is pregnant or considering pregnancy for the first time

Sample Required?

A blood sample drawn from an infant's heel by collecting a spot of blood onto filter paper; for older children or adults, a blood sample obtained by inserting a needle into a vein in the arm; sometimes a scraping of the inner cheek (buccal swab) or, for prenatal testing, amniotic fluid obtained through amniocentesis or a chorionic villus sample

Test Preparation Needed?

None

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

Cystic fibrosis (CF) is an inherited disease that affects mainly the lungs, pancreas, and sweat glands. It leads to the production of thick, sticky mucus and can cause recurrent respiratory infections and impaired function of the pancreas. The CF gene mutation panel detects the common mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on chromosome 7 to screen for or diagnose CF or to identify carriers of the disease.

Each cell in the human body (except sperm and eggs) has 46 chromosomes (23 inherited from the mother and 23 from the father). Genes on these chromosomes form the body's blueprint for producing proteins that control body functions.

Cystic fibrosis is caused by a mutation in each of the two copies of the CFTR gene (one copy from each parent). Both copies (alleles) of this gene pair must be abnormal to cause CF. If only one copy is mutated, the individual is a CF carrier. Carriers do not generally have any CF symptoms, but they can pass their abnormal CF gene copy on to their children.

To date, more than 2,000 different mutations of the CFTR gene have been identified, but only a few of the mutations are common. The majority of cystic fibrosis cases in the U.S. are caused by a mutation called deltaF508 (F508).

Recommendations by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) have led to the adoption of a standard CF gene mutation panel. It includes 23 of the most common mutations (those with frequencies greater than 0.1% in the general U.S. population).

Some laboratories use expanded panels of up to 100 or more mutations designed to detect rare mutations particular to specific ethnic populations. These may provide slightly better sensitivity to detect mutations in some ethnic populations but are not recommended by ACOG for general screening. Some rare mutations are seen in only a few individuals and may not be detected with routine testing, even with an expanded panel.

In a CF gene mutation panel, the laboratory specifically examines the CFTR gene on each chromosome 7 for the 23 mutations. If the initial panel of mutations demonstrates a single mutation, additional testing for other less common mutations may be indicated if the individual is suspected of having CF.

How is the sample collected for testing?

A blood sample is drawn from an infant's heel by collecting a spot of blood onto filter paper; for older children and adults, a blood sample is obtained by inserting a needle into a vein in the arm. A scraping of the inner cheek, called a buccal swab sample, may be collected. For prenatal testing, a sample of amniotic fluid may be collected using amniocentesis or a chorionic villus sample may be collected.

Is any test preparation needed to ensure the quality of the sample?

Cystic fibrosis (CF) gene mutation testing may be used to screen for CF in newborns in some states (all U.S. states screen for CF and some states use this test for screening), to help diagnose CF, or to determine whether an individual is a carrier of a CF genetic mutation.

The CF mutation panel can be used as part of prenatal testing to determine whether prospective parents are carriers of a CF gene mutation and therefore at risk of passing the gene mutation to future children.

The American College of Obstetricians and Gynecologists recommends that carrier screening be made available to all women of reproductive age to identify couples at risk of having a child with CF. This is typically done by sequential testing:

In a sequential strategy, the mother is usually tested first. If she is not a carrier, then any child she had would, at most, be a carrier from the father's side. Using this logic, the father is not tested.

A positive result for the mother should include the recommendation of testing her partner and at-risk family members.

All individuals with positive results for diagnostic tests or partners who are both identified as carriers should receive genetic counseling. In addition, any individuals who have a family history of CF should be referred for genetic counseling.

CF gene mutation testing can also be used for prenatal diagnosis if both parents are known to be carriers. DNA from amniocentesis and chorionic villus sampling procedures, although somewhat invasive, can be used to test the fetus for the mutations that have been identified in the parents.

CF gene mutation testing results must be interpreted in the context of the person's signs and symptoms and physical examination as well as medical and family history, ethnic background, and results of other laboratory tests.

If a CF gene mutation panel identifies two copies of gene mutations, then the person is diagnosed with cystic fibrosis. The test, however, cannot predict how severe or mild the symptoms may be. People with the exact same mutations may have very different outcomes.

If the CF gene mutation panel reveals a single copy of a mutation or is negative and the person tested has signs and symptoms of CF, then further mutation testing, a sweat chloride test, and/or other laboratory testing to evaluate organ function are warranted. The person may have a more rare form of CF that has not been identified or may have a lung or pancreatic disease or condition other than cystic fibrosis. The person may also be a carrier since some CF carriers may experience signs and symptoms related to CF.

If the CF gene mutation panel is positive for a single copy of a mutation and the person tested does not have signs and symptoms, then it is likely that the person is a CF carrier. If someone is identified as a carrier, then the siblings of this person may also want to verify their carrier status.

If the panel results are negative for mutations and the person has no signs or symptoms, then it is likely that the person does not have CF and is not a carrier. There is still a slight risk that someone who tests negative could be a carrier of a rare mutation not identified with the standard panel.

Early diagnosis of cystic fibrosis allows those affected to be referred to CF centers for specialized care, individualized treatment plans, and careful monitoring. Beginning treatments such as taking oral enzyme supplements and fat-soluble vitamins, learning how to clear mucus out of airways, and learning to recognize respiratory infections can improve a person's quality of life and minimize CF complications.

Healthcare practitioners may have varying approaches to screening and diagnosing CF, and gene mutation testing may involve a series of steps. Sometimes, a healthcare practitioner will choose to order a standard panel that includes 23 of the most common mutations. If results are negative and the clinical suspicion is still high that a person has CF, the healthcare practitioner may then request that an expanded panel be performed, or a negative result may automatically generate (reflex) a request for an expanded panel.

Based on the ancestry of the individual tested, some healthcare practitioners may immediately start with the expanded panel. In either scenario, a negative screening panel result may lead to a request for gene sequencing, a method that can identify rare mutations not detected by the standard or expanded panel.

No. To date, more than 2,000 different mutations of the CFTRgene that cause cystic fibrosis have been identified, but only a few of the mutations are common. Some laboratories use the standard panel recommended by the American College of Medical Genetics and the American College of Obstetricians and Gynecologists that tests for 23 of the most common mutations (those with frequencies greater than 0.1% in the general U.S. population). Some laboratories offer expanded panels of up to 100 or more mutations. However, even these will not detect all genetic causes of cystic fibrosis.

Yes. Generally, the frequency of CF carriers is highest in Caucasians and Ashkenazi Jewish populations and is lower in other ethnic groups. According to the American College of Obstetricians and Gynecologists, the risk of being a carrier before genetic testing for different ethnic groups are estimated as follows:

Caucasians: 1 in 25

Ashkenazi Jewish: 1 in 24

Hispanic white: 1 in 58

African American: 1 in 61

Asian American: 1 in 94

Since the ancestry of the U.S. population is becoming increasingly blended, the historical data and statistical risks are changing. Quoted risks based on ancestry are estimates, and the risk for individuals of mixed ancestry may be unknown. Some families may also carry the additional risk of specific rare mutations within their family tree.

Every state's newborn screening program includes a test for cystic fibrosis, so you will not need to request it. The method used may vary, with some states performing a blood test to determine the level of immunoreactive trypsinogen (IRT) and others screening for CF with gene mutation testing.

(2011 April, 2014 Reaffirmed). Update on Carrier Screening for Cystic Fibrosis. The American College of Obstetricians and Gynecologists. Available online at http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Update-on-Carrier-Screening-for-Cystic-Fibrosis. Accessed on 11/12/16.

(2016 February). Cystic Fibrosis: Prenatal Screening and Diagnosis. The American College of Obstetricians and Gynecologists. Available online at http://www.acog.org/Patients/FAQs/Cystic-Fibrosis-Prenatal-Screening-and-Diagnosis. Accessed on 11/12/16.

Quest Diagnostics NEWS (2002, Winter). What is the Best Test to Screen for Cystic Fibrosis? [On-line serial]. PDF available for download at http://www.questdiagnostics.com/hcp/files/02winter_newsletter.pdf through http://www.questdiagnostics.com.

Biomedical Hypertext (1999 May 20, last update). Exocrine Secretions of the Pancreas. Colorado State University [On-line information]. Available online at http://arbl.cvmbs.colostate.edu/hbooks/pathphys/digestion/pancreas/exocrine.html.

(Update April 23, 2008) National Newborn Screening and Genetics Resources Center. National Newborn Screening Status Report. Available online at http://genes-r-us.uthscsa.edu/nbsdisorders.htm. Accessed January 2009.

American College of Obstetricians and Gynecology (ACOG). Cystic fibrosis Carrier Testing: The Decision is Yours. Available online at http://www.acog.org/from_home/wellness/cf001.htm. Accessed January 2009.

Ooi, C. et. al. (2012 July 27). Comparing the American and European Diagnostic Guidelines for Cystic Fibrosis Same Disease, Different Language? Medscape Today News from Thorax. v67 (7):618-624. [On-line information]. Available online at http://www.medscape.com/viewarticle/766511. Accessed September 2012.

Ask a Laboratory Scientist

This form enables you to ask specific questions about lab tests. Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, American Society for Clinical Laboratory Science. Please allow 2-3 business days for an email response from one of the volunteers.

Thank you for using the Consumer Information Response Service ("the Service") to inquire about the meaning of your lab test results. The Service is provided free of charge by the American Society for Clinical Laboratory Science, which is one of many laboratory organizations that supports Lab Tests Online.Please note that information provided through this free Service is not intended to be medical advice and should not be relied on as such. Although the laboratory provides the largest single source of objective, scientific data on patient status, it is only one part of a complex biological picture of health or disease. As professional clinical laboratory scientists, our goal is to assist you in understanding the purpose of laboratory tests and the general meaning of your laboratory results. It is important that you communicate with your physician so that together you can integrate the pertinent information, such as age, ethnicity, health history, signs and symptoms, laboratory and other procedures (radiology, endoscopy, etc.), to determine your health status. The information provided through this Service is not intended to substitute for such consultations with your physician nor specific medical advice to your health condition.By submitting your question to this Service, you agree to waive, release, and hold harmless the American Society for Clinical Laboratory Science and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "ASCLS") and the American Association for Clinical Chemistry and its affiliates or their past or present officers, directors, employees, agents, and Service volunteers (collectively referred to as "AACC") from any legal claims, rights, or causes of action you may have in connection with the responses provided to the questions that you submit to the Service.AACC, ASCLS and its Service volunteers disclaim any liability arising out of your use of this Service or for any adverse outcome from your use of the information provided by this Service for any reason, including but not limited to any misunderstanding or misinterpretation of the information provided through this Service.